New Technologies for Human Cancer Imaging

John V. Frangioni

ABSTRACT

Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor. A meaningful impact on cancer screening, staging, and treatment is unlikely to occur until the tumor-to-background ratio improves by three to four orders of magnitude (ie, $10^3$ to $10^5$-fold), which in turn will require proportional improvements in sensitivity and contrast agent targeting. This review analyzes the physics and chemistry of cancer imaging and highlights the fundamental principles underlying the detection of malignant cells within a background of normal cells. The use of various contrast agents and radiotracers for cancer imaging is reviewed, as are the current limitations of ultrasound, x-ray imaging, magnetic resonance imaging (MRI), single-photon emission computed tomography (PET), and optical imaging. Innovative technologies are emerging that hold great promise for patients, such as positron emission mammography of the breast and spectroscopy-enhanced colonoscopy for cancer screening, hyperpolarization MRI and time-of-flight PET for staging, and ion beam-induced PET scanning and near-infrared fluorescence-guided surgery for cancer treatment. This review explores these emerging technologies and considers their potential impact on clinical care. Finally, those cancers that are currently difficult to image and quantify, such as ovarian cancer and acute leukemia, are discussed.

J Clin Oncol 26:4012-4021. © 2008 by American Society of Clinical Oncology

INTRODUCTION

There are only six imaging modalities available to clinicians who diagnose, stage, and treat human cancer: x-ray (plain film and computed tomography [CT]), ultrasound (US), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and optical imaging. Of these, only four (CT, MRI, SPECT, and PET) are capable of three-dimensional (3-D) detection of cancer anywhere in the human body.

It is important to understand that the invention and evolution of these imaging modalities were based on historical advances in physics and/or chemistry and not on the needs of oncologists. As will be described, all four 3-D imaging modalities suffer from deficiencies in sensitivity and/or resolution that preclude their ability to solve many of the most important clinical problems in cancer screening, staging, and treatment; they simply were not designed to image small numbers of cancer cells.

The root of the problem is one of scale. A typical cell in the human body is 10 μm in diameter, with a volume of only 1 pL. Hence every 1 cm$^3$ (1 g) of solid tissue contains approximately $10^9$ or one billion cells; the entire human body is estimated to contain approximately $10^{14}$ cells. Because a malignant clone evolves from a single cell, initially one would need a detectability of $10^{-14}$, an inconceivably small number, to detect the genesis of a tumor. However, solid tumors typically display Gompertzian kinetics, with a first lag phase starting from the single cell stage, a log phase heralded by angiogenesis and an escape from diffusion-limited nutrition at approximately the $10^6$ cell stage, and a second lag phase culminating in death of the patient at approximately $10^{12}$ cell (1 kg) stage (Fig 1).

The goal of cancer imaging should be to detect and/or image the smallest possible number of tumor cells, ideally before the angiogenic switch. The distinction between what we call detection and imaging is rather arbitrary and is based on the volume element (ie, voxel) size of the particular imaging modality being used. A small collection of tumor cells that is subvoxel in dimensions might be detectable, but because it occupies only a single voxel, a 3-D image is not formed. Regardless of which metric is used, the threshold for detection remains of paramount importance. Unfortunately, as explained in this article, the present detection threshold for solid tumors is approximately $10^7$ cells (1 g = 1 cm$^3$) growing as a single mass. Hence from an imaging
standpoint, the term remission literally means that there are somewhere between zero and 10⁹ malignant cells in the patient’s body (Fig 1). This level of uncertainty is unacceptable to both patient and caregiver.

The goal of this review is to inform the reader about why current imaging modalities are generally inadequate for oncology and which new technologies have the potential to improve patient care.

PRINCIPLES OF MEDICAL IMAGING

Signal-to-Background Ratio

Clinical imaging can be essentially reduced to a simple concept: the signal-to-background ratio (SBR), which in the case of cancer imaging is the tumor-to-background ratio. If the goal is to detect or to image cancer cells in the body, then the signal generated by one or more contrast mechanisms must be higher than the background caused by nonspecific signal or nearby normal cells. Even if there is adequate inherent sensitivity and resolution of an imaging modality to detect malignant cells, they will be invisible if the background is too high. To improve the SBR, one of three forms of contrast generation is used: endogenous contrast, exogenous nontargeted contrast, and exogenous targeted contrast.

Endogenous and Nontargeted Exogenous Contrast Agents

Endogenous contrast has undeniable advantages. It doesn’t require injection of a contrast agent or costly and time-consuming regulatory approval,⁴ and it is generally safe. However, in many clinical situations, endogenous contrast does not provide adequate sensitivity or specificity for detecting malignant cells and their products.

Nontargeted exogenous contrast, typically in the form of an extracellular fluid agent, is used routinely in CT and MRI. After intravenous injection, nontargeted contrast distributes throughout the extracellular space and is cleared rapidly by glomerular filtration. This simple process has been exploited extensively in radiology to indirectly highlight tumors. Because the effects of nontargeted contrast agents are indirect and relatively insensitive, a large number of academic and industrial investigators are developing agents that target malignant cells or their products directly (molecular imaging).

Exogenous Targeted Contrast Agents

The development of cancer-specific diagnostic agents is itself a 3-D problem (Fig 2). The first dimension is affinity (K_d), or more precisely, the ratio of K_d to the concentration of target sites (B_{Max}). The second dimension is biodistribution and clearance, which is a function of the hydrodynamic diameter, charge-to-mass ratio, and hydrophobicity of the contrast agent. Hydrodynamic diameter and charge-to-mass ratio are major determinants of how quickly an agent can extravasate from the vascular space to the malignant cell and how quickly background signal can be cleared from the body. As a general rule, small molecules and peptide ligands (hydrodynamic diameter \( \approx 3 \) nm) distribute quickly and clear through the kidneys but require adequate affinity and contact time for effective cancer imaging. Single-chain (hydrodynamic diameter of approximately 5 nm) and full-length antibodies (hydrodynamic diameter of approximately 10 nm) fall on a spectrum from intermediate to poor biodistribution and clearance. Traditional nanoparticles (\( \geq 10 \) nm) have virtually no clearance from the body, and even with protective coatings, eventually concentrate in the reticuloendothelial system. A new study from our laboratory has suggested the criteria (the Choi criteria⁵) for the effective use of nanoparticles in vivo. The third dimension is effect size, which for a diagnostic agent is the SBR and for a therapeutic agent is cytotoxicity. Optimizing a contrast agent or radiotracer in all three dimensions is an incredibly difficult task, which presently takes years before clinical testing can even be considered.

Fig 1. Gompertzian growth curve of a solid tumor and its relationship to cancer detection and imaging. Number of malignant cells (ordinate) as a function of time (abscissa). The transition from first lag to log phase of growth, associated with the transition from diffusion-limited nutrition to neovascularization, is labeled “angiogenic switch.” Remission is shown as the uncertainty of cell number ranging from zero to the current clinical threshold for cancer detection (approximately 10⁹ cells growing as a single mass).

Fig 2. Three-dimensional development of exogenous, targeted diagnostic or therapeutic agents. Colored box delineates optimal in vivo performance.
Additional Barriers to Effective Cancer Imaging

Generating an adequate SBR for detecting/imaging small numbers of malignant cells is made more difficult by the following barriers. First, there is a finite achievable concentration for receptor-targeted agents. The most abundant cancer-associated cell surface targets, such as prostate-specific membrane antigen\(^6\) and Erb-B2,\(^7\) are expressed at approximately \(10^7\) molecules per cell, corresponding to a cellular concentration of only 170 nmol/L. Most receptors, in fact, are expressed at levels of only \(10^3\) to \(10^4\) copies per cell (1.7 to 17 nmol/L). Second, inherent limitations of imaging modality sensitivity and resolution (Table 1) preclude detection or imaging of small numbers of cells. Third, both voluntary and physiologic motion artifacts become increasingly problematic for smaller tumors. Fourth, the body has many barriers to the effective targeting of contrast agents (and therapeutics) in vivo, including inhibitors present in plasma, a relatively small effective endothelial pore size (hydrodynamic diameter of approximately 5 nm) that constrains biodistribution,\(^5\) and basement membranes that act as barriers to preinvasive cancer detection. Finally, many solid tumors have high hydrostatic pressure, which impedes homogeneous infiltration of diagnostic agents.\(^8,9\) Enhanced permeability and retention\(^10,11\) is not discussed in this review because it has questionable relevance to the detection and treatment of preangiogenic small primaries and micrometastases.

Table 1. Sensitivity and Resolution of Cancer Imaging Modalities as a Function of Cell Number and Contrast Agent/Radiotracer Concentration

<table>
<thead>
<tr>
<th>Modality</th>
<th>Typical Voxel/Pixel Dimensions (Resolution)</th>
<th>Maximum No. of Cells per Voxel/Pixel</th>
<th>Clinically Available Exogenous Contrast Agent(s)</th>
<th>Radiotracer/Contrast Agent Hydrodynamic Diameter*</th>
<th>Contrast Agent Concentration per Voxel/Pixel Required for Detection†</th>
<th>No. of Molecules of Contrast per Voxel/Pixel Required for Detection‡</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>1 (\mu)L (1x1x1 mm)</td>
<td>(10^8)</td>
<td>Micbubbles</td>
<td>(1\ \mu)m</td>
<td>NA</td>
<td>NA</td>
<td>Microbubbles remain intravascular in most tissues</td>
</tr>
<tr>
<td>CT</td>
<td>1 (\mu)L (1x1x1 mm)</td>
<td>(10^6)</td>
<td>Iodine</td>
<td>(1\ \text{nm})</td>
<td>0.5 M</td>
<td>(3 \times 10^{17})</td>
<td>Requirement for molar concentrations precludes targeted imaging</td>
</tr>
<tr>
<td>MRI</td>
<td>1 (\mu)L (1x1x1 mm)</td>
<td>(10^6)</td>
<td>Chelated Gd(^{3+})</td>
<td>(1\ \text{nm})</td>
<td>5 (\mu)mol/L</td>
<td>(3 \times 10^{13})</td>
<td>Would require (&gt;10^4) Gd(^{3+}) atoms per cell for detectability</td>
</tr>
<tr>
<td>SPECT</td>
<td>1.7 cm(^3) (12x12x12 mm)</td>
<td>(1.7 \times 10^9)</td>
<td>(99m\text{Tc})</td>
<td>(1\ \text{nm})</td>
<td>(0.3\ \text{pM\text{#} (=8 \times 10^5 \text{Bq/voxel})})</td>
<td>(3 \times 10^6)</td>
<td>On average approximately 0.2 radioatoms per cell(\text{#})</td>
</tr>
<tr>
<td>PET</td>
<td>0.5 cm(^3) (8x8x8 mm)</td>
<td>(5 \times 10^8)</td>
<td>ICG</td>
<td>(1\ \text{nm})</td>
<td>0.02 (\text{pM\text{#} (=7 \times 10^8 \text{Bq/voxel})})</td>
<td>(6 \times 10^6)</td>
<td>On average approximately 0.01 radioatoms per cell(\text{#})</td>
</tr>
<tr>
<td>Optical (2-D)</td>
<td>0.01 mm(^2) (0.1x0.1 mm)</td>
<td>(10^7)</td>
<td></td>
<td>(1\ \text{nm})</td>
<td>(10^{-100} \text{nmol/L})</td>
<td>(6 \times 10^7)</td>
<td>Surface only NIR fluorescence, requires approximately (10^4)–(10^5) fluorophores per cell for detectability</td>
</tr>
<tr>
<td>Optical (3-D)</td>
<td>1 cm(^3) (1x1x1 cm)</td>
<td>(10^9)</td>
<td>ICG</td>
<td>(1\ \text{nm})</td>
<td>(10^{-100} \text{nmol/L})</td>
<td>(6 \times 10^{13})</td>
<td>NIR tomography-based, requires approximately (10^{10})–(10^{20}) fluorophores per cell for detectability</td>
</tr>
</tbody>
</table>

Abbreviations: US, ultrasound; NA, not applicable; CT, computed tomography; MRI, magnetic resonance imaging; Gd\(^{3+}\), gadolinium; SPECT, single photon emission computed tomography; \(99m\text{Tc}\), technetium 99m; \(111\text{In}\), indium 111; \(67\text{Ga}\), gallium 67; PET, positron emission tomography; ICG, indocyanine green; NIR, near-infrared.

*After conjugation of a targeting molecule to a contrast agent or radiotracer, final hydrodynamic diameter increases proportionally.
†Does not take into account the significant effect of background and tissue attenuation on detectability. Values shown are theoretical only.
‡Assumes 100 counts, 6 minutes scan, SPECT/PET attenuation of 0.20/1.1, sensitivity of 0.02%/0.5%, half-life of 6/1.8 hours, and maximum specific activity.
§Assuming a tumor thickness of 0.1 mm (10 cells thick).
|| Approximate resolution at a depth of 10 cm in soft tissue such as breast.

CANCER IMAGING MODALITIES

On the basis of its physics and chemistry, each cancer imaging modality has certain limitations with respect to resolution, sensitivity, and contrast generation (Table 1).

US

US uses 1 to 10 MHz sound waves to see inside soft tissue. Because sound waves are highly scattered at bone and air interfaces, many parts of the body are inaccessible, and effective imaging depth is limited in most organs to approximately 10 cm. Although resolution and endogenous contrast are quite high, exogenous contrast in the form of microbubbles must typically be 0.25 to 1 \(\mu\)m in diameter to produce adequate signal. This precludes extravasation from normal vasculature.

X-Ray Imaging

Plain films and CT use the simple principle of shining an x-ray beam through the body and measuring its attenuation. CT rotates the source/detector pair around the patient so that acquired data can be reconstructed into a 3-D image. The main limitation to x-ray imaging is that exogenous contrast agents must have a high atomic number and be at exceptionally high concentrations to attenuate x-rays. The nontargeted, exogenous agents that are currently used clinically are injected at molar...
concentrations and become invisible after only a few-fold dilution in blood. The generation of targeted CT agents for cancer imaging does not seem technically feasible (Table 1).

MRI

MRI images the small excess in the Boltzmann distribution of spins within the magnetic field. For protons (ie, hydrogen nuclei) at approximately 1.5 T, this excess represents, at most, several parts per million of the total number of hydrogen nuclei present. Because the total proton concentration in most tissue is approximately 80 M, the MRI signal is arising from approximately only 80 µmol/L of the protons present. A major trend in MRI is to improve the signal-to-noise ratio by increasing magnetic field strength from 1.5 T to 3 T and beyond. Because the signal-to-noise ratio scales linearly with field strength, increasing from 1.5 T to 7 T results in an approximately 4.7-fold improvement. Importantly, though, high field strength may introduce other problems, such as increased tissue heating and standing wave patterns present at higher radio-frequency waves.12

When intravenously injected gadolinium (Gd$^{3+}$)-based contrast agents are used, it is not the Gd$^{3+}$ being imaged, but instead, it is the effect of the Gd$^{3+}$ on the magnetic resonance relaxation properties of the protons present in the tissue. This relaxation effect is only observable at concentrations of Gd$^{3+}$ greater than approximately 50 µmol/L, making targeted agents difficult to develop.

SPECT

SPECT is a powerful tool for quantifying the distribution of a radioactive compound (ie, radiotracer) in humans. When a SPECT radioisotope decays, one or more gamma rays (ie, photons), having particular energies, are released in random directions. Because high-energy photons cannot be focused using conventional lenses, collimators are used to restrict the angle of the emitted photons that actually reach the detector. However, typical parallel-hold collimators for SPECT scanners have sensitivities of only approximately 0.02%, that is, only 1/5,000th of the decay events is measured. Also, living tissue is quite effective at attenuating photon energies of SPECT isotopes. Indeed, only 5% of 140 keV technetium 99m ($^{99m}$Tc) photons remain after traveling 25 cm through the body. When factoring in sensitivity and tissue attenuation, SPECT detects only 1/100,000th of the photons being produced at the cancer site, and the resolution is, at best, 12 × 12 × 12 mm (Table 1).

PET

Positrons, which are antimatter equal in mass but opposite in charge to an electron, are emitted from proton-rich nuclei. Depending on their energy, positrons travel an average distance (the annihilation distance) before interacting with an electron (matter). Although not always appreciated, the density of electrons in a tissue will have a profound effect on the annihilation distance. Less dense tissues, such as lung, have a longer annihilation distance, resulting in lower inherent resolution. The matter (electron) and antimatter (positron) annihilate each other and produce two antiparallel 511-keV photons. Detector crystals are mounted in a stationary ring, and only those 511-keV photons hitting opposing crystals coincidentally are counted.

The overall sensitivity of a clinical PET scanner is approximately 0.5%, and maximal resolution is approximately 8 × 8 × 8 mm (Table 1). Like SPECT isotopes, the body attenuates even 511-keV photons, with only 10% remaining after passage through 25 cm of solid tissue. When factoring in sensitivity and tissue attenuation, PET detects approximately 1/2,000th of the photons being produced at the cancer site. Because of the combined effects of background and tissue attenuation, present PET technology is only capable of detecting solid tumors ≥ 10³ cells in size.

Because most PET isotopes are difficult and expensive to synthesize or have extremely short half-lives, they are not routinely available. The exception is fluorine 18 ($^{18}$F), which has a 110-minute half-life and is available in many chemical forms. The glucose-mimetic 2-deoxy-2-[$^{18}$F]fluoro-D-glucose ($^{18}$FDG) is the most commonly used PET compound because it is taken up by metabolically active cells, is not metabolized, and is trapped intracellularly after phosphorylation by hexokinase. Many, but not all, tumors are relatively $^{18}$FDG avid (reviewed in Kelloff et al13). It is unfortunate that the term PET scanning has come to be a misnomer meaning $^{18}$FDG scanning, because $^{18}$FDG is only the first and most available $^{18}$F contrast agent. It is certainly not an ideal PET radiotracer for cancer imaging, and it has a relatively high uptake in many normal tissues and organs.14

Optical Imaging

When a photon of light interacts with living tissue, it can be absorbed or it can be scattered. Thus the two major types of optical imaging are absorption-based and scattering-based. Most optical methods use relatively simple instrumentation to image-reflected excitation light, or fluorescence emission light, from a surface. Tissue reflectance imaging is high resolution (as low as 10 µm) and fast, but because of multiple light scattering, sensitivity is limited by the 1/e optical penetration, and contrast is derived primarily from superficial structures, typically up to approximately 3 mm in depth. Tomographic optical spectroscopy and imaging (ie, diffuse optics) exploits multiple light scattering and uses computational models to reconstruct the position of absorbing and scattering structures in thick (up to 10 cm) tissues. With the increased imaging depth of diffuse optical imaging, there is a commensurate reduction in resolution compared with superficial imaging methods (Table 1).

NEW IMAGING TECHNOLOGIES FOR CANCER SCREENING

The rationale for screening is to detect cancer before metastasis, and preferably, while the tumor comprises the smallest possible number of cells. Many new technologies suggest dramatic improvements in screening over the next decade.

Breast Cancer Screening

Dedicated CT, positron emission mammography, and dynamic contrast-enhanced MRI. Recent advances in dedicated breast CT technology suggest that 3-D mammograms are now possible, with no more radiation dose than from a two-view mammogram.15 Although the results of a 45-patient, phase II study are still being analyzed, the addition of intravenous iodine contrast improved detection even further, and tumors that had not been seen with conventional mammography became visible.16

Equally exciting is the development of high-resolution, high-sensitivity positron emission mammography (PEM).17 High background uptake of $^{18}$FDG in normal dense breast tissue14 should not diminish enthusiasm for PEM because improved breast cancer-specific probes are being actively developed.18 By combining PEM with dedicated CT, or even dynamic contrast-enhanced (DCE) MRI,19 it should soon be possible to detect tumors as small as 1 mm. However,
whether patients, practitioners, and health care payers will embrace the intravenous injection of one or more diagnostic agents for a revolutionary advance in breast cancer detection remains to be seen.

**US and magnetic resonance elastography.** In 1991, US-based measurement of soft tissue strain and elastic modulus, termed elastography, was introduced by Ophir et al. Because breast lesions often differ from normal breast tissue in their mechanical properties, elastography was quickly applied to breast nodules. A recent clinical trial comparing US elastography with conventional US and mammography for breast cancer detection showed it to have the highest specificity and lowest false positive rate of the three modalities. Specificity, positive predictive value, and false-positive rate could be improved even further by combining elastography with conventional US imaging. It has also been shown that magnetic resonance can be used to measure the elastic properties of the breast, with encouraging initial clinical results in breast cancer detection.

**Contrast-Enhanced Optical Imaging of Tissue Surfaces**

Any accessible tissue surface (e.g., the skin, GI tract, and cervix) is amenable to optical imaging, and virtually every variety of noncontrast optical imaging has been studied, including diffuse reflectance, scattering spectroscopy, multiwavelength spectroscopy, autofluorescence spectroscopy, and polarization spectroscopy. Although these techniques have different sensitivities to different optical properties of tumors, they all share the major advantages of being fast, safe, and inexpensive. Depending on the precise origin of the contrast, these methods may probe from a few hundred micrometers into the tissue surface up to a few millimeters. Although blood and other endogenous substances can limit light penetration into tissue, hemoglobin sometimes provides an important contrast mechanism. Recent advances in optical coherence tomography, which is capable of providing real-time, near-histology resolution of lumenal surfaces at millimeter depths, promises to be particularly effective for carcinoma screening, especially in the GI tract (reviewed in Brand et al and DaCosta et al).

**Virtual Colonoscopy**

Over the past 5 years, tremendous progress has been made in virtual colonoscopy using CT (reviewed in Pickhardt and Kim) and MRI (reviewed in Ajaj and Goyen) methods. Although neither technique eliminates the need for a thorough bowel cleansing, both are noninvasive and do not require sedation. In a prospective comparison study, however, the sensitivity of virtual colonoscopy was lower than that of conventional colonoscopy for superficial ulcers and small polyps, and the detection of flat lesions may require fecal tagging or intravenous contrast.

**Replacement of SPECT Radiotracers With PET Radiotracers**

Given the multiple technical advantages of PET, an emerging trend is to replace SPECT imaging with PET imaging. The only two factors slowing this transition are the limited availability of the more exotic PET isotopes that are direct replacements for SPECT isotopes and the availability of PET replacements in an appropriate chemical form and half-life appropriate for biodistribution. A particularly attractive isotope for targeted PET imaging is gallium 68 (68-minute half-life), which can be chelated by the same chemical system as indium 111. For example, gallium 68–labeled octreotide imaging of neuroendocrine tumors displayed a 97% sensitivity, a 92% specificity, and an accuracy of 96%, far outperforming two different SPECT octreotide derivatives. Other PET tracers, for which there is no SPECT equivalent, are also being developed at a rapid rate.

**Time-of-Flight PET**

Traditional PET scanners make no attempt at measuring the extremely small time difference it takes antiparallel photons to reach their respective detectors. Time-of-flight PET scanners measure this time difference and are therefore able to more precisely locate the position of the originating decay event. As a general rule, time-of-flight PET scanners permit the user to choose a two-fold improvement in resolution or a two-fold improvement in sensitivity, but not both. Practical benefits of this performance improvement include achieving cancer detection, which would otherwise fall below the detection threshold, in large patients.

**Hyperpolarization MRI**

Given the exquisite anatomic imaging capability of MRI, effort has focused on improving its sensitivity to exogenous contrast agents. During the process of hyperpolarization, certain nuclei can be polarized to levels that are between 10^4 and 10^5 times higher than their Boltzmann distribution, enhancing their detectability by MRI. For example, hyperpolarized carbon 13 pyruvate permits high sensitivity detection of tumors in animals. Although the half-life of this improved spin state is typically short, the innovative use of weak magnetic fields and alternative atoms to prolong the effect are exciting avenues of investigation.

**Paramagnetic Chemical Exchange Saturation Transfer MRI**

At the present time, the only lanthanide used routinely for MRI contrast is Gd. However, recent advances in chelation chemistry and MRI pulse sequences exploit additional lanthanides and the...
mechanism of paramagnetic chemical exchange saturation transfer (reviewed in Zhang et al\textsuperscript{52}). Recent work has improved paramagnetic chemical exchange saturation transfer contrast sensitivity to the 20 to 40 μmol/L range in plasma,\textsuperscript{53} with further improvements expected by judicious choice of lanthanide and pulse sequence.

Cancer-Specific Targeting Ligands

A common approach to developing cancer-specific diagnostic agents is to chemically isolate a contrast agent or radiotracer from a separate targeting domain.\textsuperscript{54} This modular strategy permits one targeting molecule to create several diagnostic agents for different imaging modalities and vice versa. Investigators have focused on the development of cancer-specific small molecules, single-chain (scFv) antibodies, and other small proteins as targeting molecules (reviewed in Kelloff et al\textsuperscript{55}) because immunoglobulin G antibodies have inherent problems in tumor targeting, such as slow biodistribution, slow clearance, and high liver uptake. Recent developments include the multimerization (reviewed in Mammen et al\textsuperscript{56}) of small molecules to improve off-rate and affinity\textsuperscript{57,58} and the use of yeast antibody display for generating high-affinity scFvs.\textsuperscript{59}

Signal Amplification and Background Reduction

To improve the SBR, one can focus on improving the signal, lowering the background, or, ideally, both. Signal amplification is a topic that has attracted considerable attention over the last few years, but few versatile systems have been described. In general, enzymatic amplification achieved by deposition of a contrast agent or radiotracer is flawed because some agents, such as Gd\textsuperscript{3+}, generate no signal in the absence of water, and others, such as radiotracers, can be dose-limiting if deposited in normal organs. A recent innovation in optical imaging, though, is an exception. Kenmoku et al\textsuperscript{60} have developed pH-sensitive NIR fluorophores that fluoresce only after receptor-mediated endocytosis, thus greatly reducing background in normal tissues.

Image-guided therapy offers a glimpse into the era of so-called personalized medicine. The following technologies can assist the clinician in making patient-specific decisions aimed at improving the delivery of cancer treatment.

Image-Guided Chemotherapy

\textsuperscript{18}FDG-PET, \textsuperscript{99m}Tc-Annexin, DCE-MRI, and optical tomography have all been shown to be effective in monitoring the response of tumors to chemotherapy. Recent prospective clinical trials using \textsuperscript{18}FDG-PET in non–small-cell lung cancer,\textsuperscript{61} esophageal cancer,\textsuperscript{62} and lymphoma\textsuperscript{63} have demonstrated that scans obtained 1 to 3 weeks after initiation of therapy are predictive not only of response, but also of improved overall survival. \textsuperscript{99m}Tc-labeled Annexin V in conjunction with SPECT imaging was also predictive of treatment response in a wide variety of tumors.\textsuperscript{64-66} For breast cancer chemotherapy, both DCE-MRI\textsuperscript{67} and optical spectroscopy\textsuperscript{68} have proven effective in the neoadjuvant setting. The fundamental problem with all of these methods, though, is quantitative assessment of log kill.

Image-Guided Ion Beam Radiotherapy

Proton and carbon ion beam therapies, and their associated Bragg peaks, not only target tumors more precisely, but also produce in situ positrons at the site of energy delivery. These positrons can then

![Fig 1. Intraoperative image-guidance using invisible near-infrared (NIR) fluorescent light. Indocyanine green (ICG) mixed with human serum albumin (HSA) creates a sensitive lymphatic tracer (ICG:HSA)\textsuperscript{74} of 7 nm in hydrodynamic diameter. After injection (Inj) into the parenchyma of swine colon, lymphatic channels (LCs) are seen within seconds, and within 1 to 2 minutes, the sentinel lymph node (SLN) has been identified (top) and can be resected under image guidance (bottom). Shown for each are the color video (left), 800-nm NIR fluorescence (middle), and merged images (pseudocolored in green; right) of the two. Arrow shows the direction of lymph flow. All images are refreshed at 15 Hz using a previously described intraoperative NIR fluorescence imaging system.\textsuperscript{72}](image-url)
<table>
<thead>
<tr>
<th>Clinical Problem</th>
<th>Cancer/Discipline</th>
<th>New Technology</th>
<th>Advantage</th>
<th>Disadvantage</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening</td>
<td>Breast</td>
<td>Dedicated CT</td>
<td>High resolution and sensitivity</td>
<td>Ionizing radiation (same as 2-view mammogram)</td>
<td>15,16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PEM</td>
<td>High sensitivity, moderate to high resolution</td>
<td>Requires IV injection of radiotracer</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DCE-MRI</td>
<td>High resolution and specificity</td>
<td>Requires IV injection of lanthanide chelate</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diffuse optical tomography (spectroscopy)</td>
<td>Noncontrast study, safe, 3-D, quantitative, high specificity, can be combined with MRI</td>
<td>Low resolution, low to moderate sensitivity</td>
<td>27-29</td>
</tr>
<tr>
<td>Endoscopy/colonoscopy/colposcopy</td>
<td>Optical (diffuse reflectance)</td>
<td>Fast, inexpensive, safe</td>
<td>Surface imaging only, interference from blood</td>
<td></td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Optical (photon scattering)</td>
<td>Fast, inexpensive, safe</td>
<td>Surface imaging only, interference from blood</td>
<td></td>
<td>32-34</td>
</tr>
<tr>
<td></td>
<td>Optical (multi-wavelength spectroscopy)</td>
<td>Fast, inexpensive, safe</td>
<td>Surface imaging only, interference from blood</td>
<td></td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Optical (autofluorescence spectroscopy)</td>
<td>Fast, inexpensive, safe</td>
<td>Surface imaging only, interference from blood</td>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Optical (polarization spectroscopy)</td>
<td>Fast, inexpensive, safe</td>
<td>Surface imaging only, interference from blood</td>
<td></td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Optical coherence tomography</td>
<td>Fast, high resolution, safe</td>
<td>Limited depth to ~2 mm, endogenous contrast only</td>
<td></td>
<td>38,39</td>
</tr>
<tr>
<td>Virtual colonoscopy</td>
<td>CT-based</td>
<td>Noninvasive, relatively fast</td>
<td>Uses ionizing radiation, difficulty with flat lesions and small polyps</td>
<td></td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>MRI-based</td>
<td>Noninvasive, relatively fast</td>
<td>Difficulty with flat lesions and small polyps</td>
<td></td>
<td>44</td>
</tr>
<tr>
<td>Staging</td>
<td>PET</td>
<td>Replacements for SPECT radiotracers</td>
<td>Higher sensitivity and resolution</td>
<td>Desired half-life not always available</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Time-of-flight detection</td>
<td>2-fold higher resolution or sensitivity</td>
<td>Limited availability</td>
<td></td>
<td>48,49</td>
</tr>
<tr>
<td>MRI</td>
<td>Hyperpolarization</td>
<td>High sensitivity possible, in vivo tracking of molecule metabolism</td>
<td>Relatively short relaxation times of agents tested to date</td>
<td></td>
<td>50,51</td>
</tr>
<tr>
<td>MRI</td>
<td>PARACEST</td>
<td>Higher sensitivity than traditional lanthanide imaging</td>
<td>Sensitivity not yet adequate for receptor-based imaging</td>
<td></td>
<td>53</td>
</tr>
<tr>
<td>All</td>
<td>Low-molecular weight targeting ligands</td>
<td>Rapid biodistribution and clearance</td>
<td>Tumor contact time often inadequate</td>
<td></td>
<td>54-59</td>
</tr>
<tr>
<td></td>
<td>Signal amplification/background reduction (optical)</td>
<td>Improved SBR</td>
<td>Requires endocytosis and pH-dependent activation</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td>Treatment</td>
<td>Chemotherapy</td>
<td>Image-guided treatment (¹⁸FDG-PET)</td>
<td>Highly sensitive</td>
<td>Expensive, not all tumors FDG-avid, difficult to quantify log kill</td>
<td>61-63</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Image-guided treatment (⁹⁹mTc-Annexin V)</td>
<td>Moderately sensitive</td>
<td>Presently unavailable, difficult to quantify log kill</td>
<td>64-66</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Image-guided treatment (DCE-MRI)</td>
<td>No ionizing radiation</td>
<td>Requires intravenous injection of lanthanide chelate, difficult to quantify log kill</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
<td>Image-guided treatment (optical spectroscopy)</td>
<td>No ionizing radiation, fast, safe, quantitative, high sensitivity and specificity</td>
<td>Low resolution, moderate sensitivity, difficult to quantify log kill</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Ion beam-induced PET and PET/CT</td>
<td>Near real-time feedback on dose delivery</td>
<td>Requires specialized and expensive infrastructure, difficult mathematical modeling</td>
<td></td>
<td>69</td>
</tr>
<tr>
<td>Surgery</td>
<td>Optical (reflectance NIR fluorescence)</td>
<td>Fast, real-time, high sensitivity and specificity</td>
<td>Poor depth penetration (~1-3 mm)</td>
<td></td>
<td>70-72,79,81,82,84</td>
</tr>
<tr>
<td></td>
<td>Optical (tomographic NIR fluorescence)</td>
<td>Depth penetration up to several cm, quantitative, high specificity</td>
<td>Requires separate acquisition and reconstruction, low to moderate resolution, low to moderate sensitivity</td>
<td></td>
<td>73</td>
</tr>
</tbody>
</table>

Abbreviations: CT, computed tomography; PEM, positron emission mammography; IV, intravenous; DCE, dynamic contrast-enhanced; MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography; PARACEST, paramagnetic chemical exchange saturation transfer; SBR, signal-to-background ratio; ¹⁸FDG, 2-deoxy-2-[¹⁸F]fluoro-D-glucose; ⁹⁹mTc, technetium 99m; NIR, near-infrared.
be used to image and quantify radiotherapy delivery using PET or PET/CT scanning. 60 3-D feedback of ion beam therapy is under intense investigation and promises significant improvements in the precision of dose delivery.

**Image-Guided Surgery**

The only two imaging techniques used even occasionally during oncologic surgery are x-ray fluoroscopy (for angiography) and US (for mass detection). However, the former exposes patients and caregivers to ionizing radiation, the latter requires direct contact with tissue, and neither can be used with targeted contrast agents. Optical imaging that exploits invisible NIR fluorescent light (700 to 900 nm) offers several advantages for image-guided surgery, including low inherent autofluorescence background, highly sensitive and specific detection of tumors up to millimeters deep in scattering tissue, and real-time imaging (reviewed in Frangioni70). Intraoperative imaging systems developed by our laboratory also provide simultaneous acquisition of surgical anatomy (color video) and function (NIR fluorescence).71,72 Innovative work from other groups has extended depth penetration to several centimeters using frequency-domain photon migration (optical tomography) techniques.73

Presently, the only clinically available NIR fluorophore is indocyanine green, which is a nontargeted extracellular fluid agent approved for nonfluorescence indications. Nevertheless, by simply mixing indocyanine green with human serum albumin, a highly fluorescent 7-nm (hydrodynamic diameter) complex is formed,74 which can be used for NIR fluorescent sentinel lymph node mapping of virtually any tissue or organ (Fig 3).72,75-78 Many investigators are also developing NIR fluorophores targeted specifically to human cancer and normal structures.79-83 If translated to the clinic, these targeted NIR fluorescent contrast agents would permit the oncologic surgeon to resect malignant cells under direct visualization while actively avoiding critical structures such as vessels and nerves.

**Ovarian Cancer**

Ovarian cancer arises from a monolayer of flat-to-cuboidal cells called the ovarian surface epithelium; hence the earliest proliferative lesion is only approximately 10 μm thick. As such, early-stage ovarian cancer, and even small metastases, are difficult to image using conventional technology. Optical imaging, though, is especially well suited for sensitive and rapid interrogation of large surfaces. Penson et al84 at Fox Chase Cancer Center have shown that intravenous injection of indocyanine green in conjunction with a specially designed laparoscope could permit image-guided debulking of peritoneal metastases. It is intriguing to speculate whether such technology might also someday aid in the screening of high-risk populations.

**Acute Leukemia**

Recent evidence points to a so-called stem-cell niche in the bone marrow that is required for sustenance of acute leukemia.85 Although the bone marrow is well vascularized, which aids in contrast agent biodistribution to the target cells, the small number of malignant and normal cells comprising the niche, the need for signal amplification, and most important, high background from normal bone marrow cells make detection and imaging of leukemic stem cells extremely difficult.

**Pediatric Cancer**

There are only approximately 12,000 total cases of cancer in children age 0 to 18 years each year in the United States, comprising dozens of types and subtypes.86 Although there are a few successful diagnostic agents used routinely in clinical care,87 small market sizes and difficulties in performing clinical trials contribute to significant unmet need in this patient population.
REFERENCES

New Technologies for Human Cancer Imaging